Zylox-Tonbridge Medical Technology Co., Ltd.
歸創通橋醫療科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT
NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR ZYLOX® PHOENIX PERIPHERAL DETACHABLE FIBROUS COIL EMBOLIZATION SYSTEM

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the "**Company**", together with its subsidiary, the "**Group**") on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that the ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System, self-developed by the Group, has recently been granted marketing approval by the National Medical Products Administration (the "**NMPA**"). This is the Company's first product launched for peripheral vascular embolization interventional procedures. As of the date of this announcement, the Company has obtained approvals from the NMPA for a total of 34 products in the People's Republic of China (the "**PRC**").

ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System is a domestically developed medical device for minimally invasive interventional treatment of peripheral arterial embolism. The clinical application of coils for vascular embolization has been prevalent in the field of peripheral vascular intervention. For instance, endoleak management of abdominal aortic aneurysms, embolization treatment of visceral aneurysms, hemoptysis and arteriovenous fistula are important clinical applications, and their safety and efficacy have been internationally recognized. At present, in China's peripheral vascular intervention device market, fibrous coils are still dominated by imported brands. The launch of the ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System can effectively fill the gap in the field of domestically developed arterial embolization devices and provides doctors and patients with high-quality and affordable products and solutions.

Based on the existing embolization coil products, the ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System optimizes and upgrades the interlocking arm detaching structure, which will enhance the cornering ability of the embolization coils and reduce the risk of premature detaching. Moreover, this product specifically adds polypropylene anti-untwisting wire, which further solves the technical challenge of premature untwisting of embolization coils. Compared with similar products currently available in the market, the ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System is available in a wider range of length and diameter specifications, providing more options to meet the needs of various vascular embolization scenarios.

The pre-marketing clinical registration trial of the ZYLOX® Phoenix Peripheral Detachable Fibrous Coil Embolization System was led by Professor Zhao Jichun from West China Hospital of Sichuan University. A total of 101 patients from 14 top clinical trial centers across the PRC were enrolled, and the immediate postoperative target vessel subtotal occlusion rate reached 100%. During the follow-up visits with all 101 subjects, no patient needed further interventional treatment or surgery in the target vessel embolization segment or aneurysm. Such excellent clinical trial results strongly demonstrate the safety and efficacy of this product.

By order of the board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, December 29, 2023

As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.